1. Home
  2. SRDX vs TNXP Comparison

SRDX vs TNXP Comparison

Compare SRDX & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRDX
  • TNXP
  • Stock Information
  • Founded
  • SRDX 1979
  • TNXP 2007
  • Country
  • SRDX United States
  • TNXP United States
  • Employees
  • SRDX N/A
  • TNXP N/A
  • Industry
  • SRDX Medical/Dental Instruments
  • TNXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SRDX Health Care
  • TNXP Health Care
  • Exchange
  • SRDX Nasdaq
  • TNXP Nasdaq
  • Market Cap
  • SRDX 415.4M
  • TNXP 365.8M
  • IPO Year
  • SRDX 1998
  • TNXP N/A
  • Fundamental
  • Price
  • SRDX $35.41
  • TNXP $47.70
  • Analyst Decision
  • SRDX Buy
  • TNXP Buy
  • Analyst Count
  • SRDX 2
  • TNXP 1
  • Target Price
  • SRDX $43.00
  • TNXP $70.00
  • AVG Volume (30 Days)
  • SRDX 209.2K
  • TNXP 1.5M
  • Earning Date
  • SRDX 08-12-2025
  • TNXP 08-15-2025
  • Dividend Yield
  • SRDX N/A
  • TNXP N/A
  • EPS Growth
  • SRDX N/A
  • TNXP N/A
  • EPS
  • SRDX N/A
  • TNXP N/A
  • Revenue
  • SRDX $121,575,000.00
  • TNXP $10,041,000.00
  • Revenue This Year
  • SRDX N/A
  • TNXP $22.87
  • Revenue Next Year
  • SRDX $3.19
  • TNXP $711.66
  • P/E Ratio
  • SRDX N/A
  • TNXP N/A
  • Revenue Growth
  • SRDX N/A
  • TNXP N/A
  • 52 Week Low
  • SRDX $26.00
  • TNXP $6.76
  • 52 Week High
  • SRDX $41.32
  • TNXP $130.00
  • Technical
  • Relative Strength Index (RSI)
  • SRDX 64.76
  • TNXP 60.36
  • Support Level
  • SRDX $34.64
  • TNXP $35.66
  • Resistance Level
  • SRDX $38.10
  • TNXP $50.39
  • Average True Range (ATR)
  • SRDX 1.48
  • TNXP 4.24
  • MACD
  • SRDX 0.20
  • TNXP -0.41
  • Stochastic Oscillator
  • SRDX 65.50
  • TNXP 81.68

About SRDX Surmodics Inc.

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Share on Social Networks: